Cargando…
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
BACKGROUND: In Australia, government-subsidised access to high-cost medicines is "targeted" to particular sub-sets of patients under the Pharmaceutical Benefits Scheme to achieve cost-effective use. In order to determine how this access system could be improved, the opinions of key stakeho...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2231358/ https://www.ncbi.nlm.nih.gov/pubmed/18096055 http://dx.doi.org/10.1186/1743-8462-4-26 |